Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Monoamine receptor sensitivity changes following chronic administration of MDL 72394, a site-directed inhibitor of monoamine oxidase.

Palfreyman MG, Mir AK, Kubina M, Middlemiss DN, Richards M, Tricklebank MD, Fozard JR.

Eur J Pharmacol. 1986 Oct 14;130(1-2):73-89.

PMID:
3780861
2.

Inhibition of monoamine oxidase selectively in brain monoamine nerves using the bioprecursor (E)-beta-fluoromethylene-m-tyrosine (MDL 72394), a substrate for aromatic L-amino acid decarboxylase.

Palfreyman MG, McDonald IA, Fozard JR, Mely Y, Sleight AJ, Zreika M, Wagner J, Bey P, Lewis PJ.

J Neurochem. 1985 Dec;45(6):1850-60.

PMID:
3840523
3.

Chronic MAO A and MAO B inhibition decreases the 5-HT1A receptor-mediated inhibition of forskolin-stimulated adenylate cyclase.

Sleight AJ, Marsden CA, Palfreyman MG, Mir AK, Lovenberg W.

Eur J Pharmacol. 1988 Sep 23;154(3):255-61.

PMID:
3234480
4.

Design and early clinical evaluation of selective inhibitors of monoamine oxidase.

Palfreyman MG, McDonald IA, Bey P, Schechter PJ, Sjoerdsma A.

Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(6):967-87.

PMID:
3266532
5.

Changes in alpha- and beta-receptor densities in rat brain as a result of treatment with monoamine oxidase inhibiting antidepressants.

Cohen RM, Campbell IC, Dauphin M, Tallman JF, Murphy DL.

Neuropharmacology. 1982 Apr;21(4):293-8.

PMID:
6123960
8.
9.
10.

The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.

Fozard JR, Zreika M, Robin M, Palfreyman MG.

Naunyn Schmiedebergs Arch Pharmacol. 1985 Nov;331(2-3):186-93.

PMID:
3937059
11.

Selective MAO A and B inhibitors: their mechanism of action and pharmacology.

Finberg JP, Youdim MB.

Neuropharmacology. 1983 Mar;22(3 Spec No):441-6. Review.

PMID:
6304562
12.

The acute effect of the bioprecursor of the selective brain MAO-A inhibitor, MDL 72392, on rat pineal melatonin biosynthesis.

Oxenkrug GF, Requintina PJ, Yuwiler A, Palfreyman MG.

J Neural Transm Suppl. 1994;41:377-9.

PMID:
7931254
13.
14.
15.

Neurochemical profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.

Da Prada M, Kettler R, Keller HH, Burkard WP, Muggli-Maniglio D, Haefely WE.

J Pharmacol Exp Ther. 1989 Jan;248(1):400-14.

PMID:
2783611
16.

The effects of chronic treatment with amitriptyline and MDL 72394 on the control of 5-HT release in vivo.

Sleight AJ, Smith RJ, Marsden CA, Palfreyman MG.

Neuropharmacology. 1989 May;28(5):477-80.

PMID:
2725855
17.
19.

Suppression of the hypo- and hyperthermic responses to 5-HT agonists following the repeated administration of monoamine oxidase inhibitors.

Gudelsky GA, Koenig JI, Jackman H, Meltzer HY.

Psychopharmacology (Berl). 1986;90(3):403-7.

PMID:
2947256

Supplemental Content

Support Center